Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Proteomics and AI bring earlier risk prediction into sharper focus

19

Apr 2026

Proteomics and AI bring earlier risk prediction into sharper focus

This review examines how high-throughput proteomics is expanding precision medicine by improving biomarker discovery, disease prediction, and drug development. It also shows how AI is helping researchers interpret complex proteomic data while highlighting major barriers such as standardization, validation, and clinical translation.

Why clinical proteomics faces a mass spectrometry vs. high-throughput profiling dilemma

19

Apr 2026

Why clinical proteomics faces a mass spectrometry vs. high-throughput profiling dilemma

This Clinical Chemistry and Laboratory Medicine review examines a central challenge in precision medicine: whether medical laboratories should prioritize metrologically sound, proteoform-resolving protein quantification by mass spectrometry or adopt scalable, affinity-based proteome profiling platforms built for high-throughput discovery and machine learning. It concludes that while emerging proteomics technologies expand diagnostic possibilities, careful validation, standardization, and quality assurance will be essential, with a hybrid path likely offering the most practical way forward.

What still drives childhood vaccine gaps in the United States

19

Apr 2026

What still drives childhood vaccine gaps in the United States

A nationwide analysis of provider-verified NIS-Child data from 2010 to 2023 found that US childhood vaccination coverage remained generally high but was consistently shaped by social and structural factors such as maternal education, income, insurance, language, and region. The study also showed that coverage of the combined seven-vaccine series rose over time, yet persistent disparities remained, especially for vaccines such as influenza, hepatitis A, and rotavirus.

Climate change could make humidity-driven heat risks more dangerous, study finds

19

Apr 2026

Climate change could make humidity-driven heat risks more dangerous, study finds

Researchers analyzing 2.46 million ambulance dispatches across 13 Chinese cities found that humidity can intensify the health risks linked to both hot and cold temperatures, with cold-dry and warm-wet conditions posing the greatest risks. Future climate projections suggest compound temperature-humidity events will become more frequent and increasingly shift health burdens toward heat-related events in China.

Generative AI may help scientists connect the many layers of cancer

19

Apr 2026

Generative AI may help scientists connect the many layers of cancer

A Cell Perspective argues that generative AI models could help tackle cancer’s multiscale, multimodal complexity by complementing the Hallmarks of Cancer framework. It proposes that models capable of complex pattern recognition, multimodal fusion, and contextual reasoning could improve cancer detection, biological discovery, and precision oncology, while still requiring rigorous validation and human oversight.

AGA update calls for better surveillance of hepatocellular carcinoma

17

Apr 2026

AGA update calls for better surveillance of hepatocellular carcinoma

A new update from the American Gastroenterological Association (AGA) urges stronger prevention efforts and better early-detection tools for hepatocellular carcinoma (HCC), the leading cause of cancer-related death in patients with cirrhosis, and the third most common cause of cancer-related death worldwide.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.